Function-oriented synthesis: Biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy

Susan L Mooberry, Michael K. Hilinski, Erin A. Clark, Paul A. Wender

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Laulimalide is a potent microtubule stabilizing agent and a promising anticancer therapeutic lead. The identification of stable, efficacious and accessible analogues is critical to clinically exploiting this novel lead. To determine which structural features of laulimalide are required for beneficial function and thus for accessing superior clinical candidates, a series of side chain analogues were prepared through a last step cross metathesis diversification strategy and their biological activities were evaluated. Five analogues, differing in potency from 233 nM to 7.9 μM, effectively inhibit cancer cell proliferation. Like laulimalide, they retain activity against multidrug resistant cells, stabilize microtubules and cause the formation of aberrant mitotic spindles, mitotic accumulation, Bcl-2 phosphorylation and initiation of apoptosis. Structural modifications in the C23-C27 dihydropyran side chain can be made without changing the overall mechanism of action, but it is clear that this subunit has more than a bystander role.

Original languageEnglish (US)
Pages (from-to)829-838
Number of pages10
JournalMolecular Pharmaceutics
Volume5
Issue number5
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Microtubules
Spindle Apparatus
Excipients
Phosphorylation
Cell Proliferation
Apoptosis
laulimalide
Neoplasms
Lead
Therapeutics

Keywords

  • Antimitotics
  • Laulimalide
  • Laulimalide analogues
  • Metathesis
  • Microtubule stabilizers
  • Synthetic chemistry

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Function-oriented synthesis : Biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy. / Mooberry, Susan L; Hilinski, Michael K.; Clark, Erin A.; Wender, Paul A.

In: Molecular Pharmaceutics, Vol. 5, No. 5, 09.2008, p. 829-838.

Research output: Contribution to journalArticle

@article{2235a277995f40918c5b63a8a1df37e8,
title = "Function-oriented synthesis: Biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy",
abstract = "Laulimalide is a potent microtubule stabilizing agent and a promising anticancer therapeutic lead. The identification of stable, efficacious and accessible analogues is critical to clinically exploiting this novel lead. To determine which structural features of laulimalide are required for beneficial function and thus for accessing superior clinical candidates, a series of side chain analogues were prepared through a last step cross metathesis diversification strategy and their biological activities were evaluated. Five analogues, differing in potency from 233 nM to 7.9 μM, effectively inhibit cancer cell proliferation. Like laulimalide, they retain activity against multidrug resistant cells, stabilize microtubules and cause the formation of aberrant mitotic spindles, mitotic accumulation, Bcl-2 phosphorylation and initiation of apoptosis. Structural modifications in the C23-C27 dihydropyran side chain can be made without changing the overall mechanism of action, but it is clear that this subunit has more than a bystander role.",
keywords = "Antimitotics, Laulimalide, Laulimalide analogues, Metathesis, Microtubule stabilizers, Synthetic chemistry",
author = "Mooberry, {Susan L} and Hilinski, {Michael K.} and Clark, {Erin A.} and Wender, {Paul A.}",
year = "2008",
month = "9",
doi = "10.1021/mp800043n",
language = "English (US)",
volume = "5",
pages = "829--838",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Function-oriented synthesis

T2 - Biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy

AU - Mooberry, Susan L

AU - Hilinski, Michael K.

AU - Clark, Erin A.

AU - Wender, Paul A.

PY - 2008/9

Y1 - 2008/9

N2 - Laulimalide is a potent microtubule stabilizing agent and a promising anticancer therapeutic lead. The identification of stable, efficacious and accessible analogues is critical to clinically exploiting this novel lead. To determine which structural features of laulimalide are required for beneficial function and thus for accessing superior clinical candidates, a series of side chain analogues were prepared through a last step cross metathesis diversification strategy and their biological activities were evaluated. Five analogues, differing in potency from 233 nM to 7.9 μM, effectively inhibit cancer cell proliferation. Like laulimalide, they retain activity against multidrug resistant cells, stabilize microtubules and cause the formation of aberrant mitotic spindles, mitotic accumulation, Bcl-2 phosphorylation and initiation of apoptosis. Structural modifications in the C23-C27 dihydropyran side chain can be made without changing the overall mechanism of action, but it is clear that this subunit has more than a bystander role.

AB - Laulimalide is a potent microtubule stabilizing agent and a promising anticancer therapeutic lead. The identification of stable, efficacious and accessible analogues is critical to clinically exploiting this novel lead. To determine which structural features of laulimalide are required for beneficial function and thus for accessing superior clinical candidates, a series of side chain analogues were prepared through a last step cross metathesis diversification strategy and their biological activities were evaluated. Five analogues, differing in potency from 233 nM to 7.9 μM, effectively inhibit cancer cell proliferation. Like laulimalide, they retain activity against multidrug resistant cells, stabilize microtubules and cause the formation of aberrant mitotic spindles, mitotic accumulation, Bcl-2 phosphorylation and initiation of apoptosis. Structural modifications in the C23-C27 dihydropyran side chain can be made without changing the overall mechanism of action, but it is clear that this subunit has more than a bystander role.

KW - Antimitotics

KW - Laulimalide

KW - Laulimalide analogues

KW - Metathesis

KW - Microtubule stabilizers

KW - Synthetic chemistry

UR - http://www.scopus.com/inward/record.url?scp=56049100275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049100275&partnerID=8YFLogxK

U2 - 10.1021/mp800043n

DO - 10.1021/mp800043n

M3 - Article

C2 - 18662015

AN - SCOPUS:56049100275

VL - 5

SP - 829

EP - 838

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 5

ER -